Article
CAV2 Confers Cetuximab Resistance in HNSCC by Ubiquitin-Mediated Disruption of the PACT-PKR Tumor Suppressor Axis
2026-03-04
Abstract excerpt
<h4>Background: </h4> /Objectives: Head and neck squamous cell carcinoma (HNSCC) frequently exhibits resistance to targeted therapies, including cetuximab. Identifying key drivers of tumor progression and elucidating the mechanisms underlying therapeutic resistance are essential for improving clinical outcomes. This study aimed to investigate the role of Caveolin-2 (CAV2) in HNSCC proliferation and cetuximab resis...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 135d4d58-cd73-59bf-b507-4a0ae44c27e5
- DOI
- 10.20944/preprints202603.0337.v1
